PRKAA2 and Obesity: Overall, the evidence suggest that central AMPK is a potential target for the treatment of obesity, an idea that is reinforced by AMPK’s effects on energy expenditure (40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50) (see below).